Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single-dose nemolizumab in Japanese atopic dermatitis patients with moderate to severe pruritus
jRCT2080225290Phase 1Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nemolizumab in atopic dermatitis (AD), sponsored by Maruho Co., Ltd. Primary endpoint: Systemic cytokine changes after nemolizumab. Started Jul 2020; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080225290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225290.